Targeted Muscle Reinnervation (TMR) or Regenerative Peripheral Nerve Interface (RPNI) for pain prevention in patients with limb amputation: a protocol for a systematic review and meta-analysis

Jesús del Moral Preciado, David Gurpegui Gámiz, Montserrat Royo Taberner, Bernardo Hontanilla Calatayud

Correspondence to David Gurpegui Gámiz; dgurpegui@unav.es

ABSTRACT

Introduction

Regenerative Peripheral Nerve Interface (RPNI) and Targeted Muscle Reinnervation (TMR) are two reinnervation techniques which have shown clear superiority over classical amputation. It is mainly due to a lower incidence of painful neuromas, residual limb pain and phantom limb pain associated with these new procedures.

However, they have never been compared to each other. Neither has their effectiveness been evaluated based on patients demographics, age, sex, comorbidities (diabetes, coronary heart disease, peripheral arterial disease, chronic kidney disease, congestive heart failure), amputations cause, type of amputation, amputation level, previous surgeries and if there was or not previous nerve division into fascicles. Therefore, the objective of this systematic review and meta-analysis is to compile all the evidence to date and provide a comprehensive view of what each technique offers.

Methods and design

The review will be conducted according to this protocol, following the recommendations of the 'Cochrane Handbook for Systematic Reviews'. A comprehensive electronic search will be performed in: Cochrane Register of Controlled Trials (CENTRAL), Web of Science, Scopus, PubMed and MedRixb. This review will include randomized, quasi-randomized, and observational studies written in English and Spanish. We will use Covidence for assessing all titles and abstracts identified during the literature search. Two review authors will independently assess the trial eligibility, risk of bias and extract appropriate data points.

Ethics and dissemination

The proposed systematic review will collect and analyse data from published studies; therefore,

it raises no ethical issues. The results of the review will be disseminated by publication in a

peer-review journal and submitted for presentations at conferences.

Keywords: Systematic review, Meta-Analysis, Pain management, Neuroma, TMR, RPNI,

Amputation.

PROSPERO registration number: CRD42024617299

37 STRENGTHS AND LIMITATIONS OF THIS STUDY

- This will be the first systematic review to include a comparison between RPNI and TMR.

- Through a comprehensive search and selection of high-quality articles, the best

available evidence of RPNI and TMR against classical amputation will be gathered.

- Gray literature and unpublished studies will be sourced from MedRixb aiming to reduce

the impact of a possible publication bias.

- Exclusion of non-English/Spanish papers may lead to language bias.

45 PICO QUESTION

46 Population

47 Any adults (aged over 18 years) and gender with a superior or inferior limb amputation.

48 Intervention

49 Prophylactic Targeted Muscle Reinnervation (TMR) or Regenerative Peripheral Nerve Interface

50 (RPNI).

51 Comparators

52 Classical amputation.

53 TMR vs RPNI.

54 Outcomes

55 1) Incidence of neuroma, 2) Incidence of residual limb pain (RLP), 3) Severity of Pain 4)

56 Incidence of phantom limb pain (PLP), and 5) Surgical complications (dehiscence, infection,

57 haematoma and seroma).

INTRODUCTION

Description of the condition

Limb amputation has an estimated incidence of 185,000 persons each year in the United States (1) with a tendency towards increasing prevalence (2). This significant increase is widely accepted to be caused by the ageing of the population and an increasing incidence of diabetes mellitus and vascular disease (2).

Amputations still cause significant morbidity and pain (3). Amputations are associated with depression as a reaction to the sudden disability (4), surgical site infection, increased risk of thromboembolism in patients subjected to a major amputation (5–8). And a significant risk of perioperative morbidity and mortality, generally in patients with vascular disease (9). In fact, the overall 5-year mortality rate in patients with any amputation ranged from 53% to 100% and from 52% to 80% for patients with major amputations, being age, renal disease, proximal amputation, diabetes, and peripheral vascular disease the risk factors. This indicates amputation as a possible prognostic severity marker (10).

Some demographic factors have shown a higher risk of incidence of amputations, Black and Latino patients being up to four (11), and one and a half (12) times respectively more likely to receive amputations when compared to white patients.

The most common aetiologies for lower limb loss are: 1) vascular pathology (mainly ischaemia due to peripheral artery disease or embolism, and diabetes mellitus), 2) trauma, 3) cancer, and 4) congenital abnormalities. On the other hand, aetiologies for upper extremity amputation in adults are 1) trauma, 2) ischaemia, 3) infection, and 4) malignancy (2,13,14).

Nerves are completely encased in an epineural sheath, which is made of well-organized fibrous connective tissue. Significant disruption of this sheath occurs during (the process of) an amputation, causing disorganized regeneration of the enclosed axons, and proliferation into scar and connective tissue, resulting in an amputation neuroma (15,16). This type of neuroma belongs to a class of tumours referred to as reactive tumours, which are considered as benign non-neoplastic nerve tumours. Although benign, they may be symptomatic, evolving into severe pathology, generating pain with numbness or paresthesias, decreasing quality of life, forcing medication and preventing prosthetic use (15–18).

87 Though benign, they can become symptomatic, transforming into severe pathologies by

88 producing

89 Some authors have described a series of criteria to classify neuromas as symptomatic (16). See

90 **Table 1.**

Table 1. Arnold's criteria for classifying neuromas as symptomatic
Mandatory criteria (must be all 3): 1. Pain with at least 3 of the following characteristics: burning, sharp, shooting, electric, paresthesias, numbness, cold intolerance. 2. Symptoms in a defined neural anatomic distribution. 3. History of nerve injury or suspected nerve injury.
Partial criteria (at least 1): 1. Positive Tinel Sign (for cutaneous nerve). 2. Positive response to local anaesthetic injection. 3. US or MRI confirmation of neuroma.

Although the incidence of symptomatic neuromas is not fully known, multiple studies have

indicated that it is in a range between 4% and 49%. This varies depending on the affected limb,

the height of the amputation, previous comorbidities, cause of surgery, and the patient's follow-

up time. (16,18–23).

The pain associated with limb amputation is known as residual limb pain (RLP) or phantom limb

pain (PLP). The mechanisms and pathophysiology of RLP and PLP are different and have not

been fully elucidated. Peripheral mechanisms include spontaneous activity in dorsal root

ganglion neurons and ectopic neural activity originating from afferent fibres in a neuroma

(24,25), while central mechanisms include spinal cord sensitization and cortical reorganization

(26–29). Both residual limb pain and phantom limb pain can occur independently or

concurrently in the post-operative period. It is thought that RLP may result from neuromas in the

stump and PLP may be more closely related to cortical reorganization (13,30).

PLP is defined as the perception of sensations, including pain, in an amputated limb or a part of

the body that is no longer present. PLP is a common sequel of amputation, occurring in up to 60

to 80% of people with limb amputation in the early post-operative period, with the incidence

decreasing with time following amputation. PLP incidence appears to be independent of age,

sex, amputation level or side. Prevention by peripheral analgesia has not yielded consistent

results (26,31–33).

RLP is defined as a type of pain felt in the part of a limb that remains after an amputation. Acute

residual limb pain is a strong predictor of chronic residual limb pain, while age, sex, amputation

level, aetiology and postsurgical pain medication quantity do not correlate with chronic residual

limb pain (30,34,35).

The psychological impact of these two entities should not be overlooked. People with limb

amputations usually experience increased anxiety, depressive symptoms, post-traumatic

psychological stress symptoms and affective distress (36,37).

De Lange et al. (38) and Mauch et al. (39) demonstrated that prophylactically intervention with

TMR or RPNI improved both residual limb pain and phantom limb pain post-amputation. It

appears that performing these techniques does not increase the complication rate beyond

prolonging surgical time. However, the superiority of one of the two techniques remains to be

demonstrated, as studies comparing them are still scarce. We aim to group all these studies to

estimate whether one technique is superior to the other in pain prevention or presents a lower

complication rate.

Description of the interventions

TMR is increasingly being used to treat symptomatic neuromas. In this procedure, severed

motor nerves are transferred to the motor branches of nearby healthy muscle segments, which,

after reinnervation, gain the capacity of contraction in response to neural control signals (40–

42). Due to the creation of multiple additional control sites, the contraction of target muscles and

the functional control of the prosthesis become easier and more intuitive. This way, it has been

demonstrated that TMR presents clear benefits compared to classical amputation, although its

ability to reduce the incidence of neuromas, as well as the treatment of PLP and RLP, is still

being investigated (41–43).

Other authors, on the other hand, carry out this technique by rerouting the severed nerve

endings to nearby expendable motor nerve branches of functionally expendable muscles,

providing a pathway for axonal growth to these nerves. This serves as biological amplifiers of

neural information and limits the regeneration that leads to neuroma formation (44,45).

RPNI involves taking a free muscle graft from the amputated limb (either proximal or distal to

the site of amputation) and encasing the muscle graft around the dissected nerve, allowing for

greater control over nerve growth to motor end plates on the grafted tissue ((46–59)).

Those autologous free muscle grafts are designed to be small enough to have an easy

revascularization and to provide living motor end plates suitable for reinnervation in

approximately 1–3 months. It has a great potential for permitting the use of advanced

neuroprosthetics or sensory feedback (46,60–64).

TMR is more demanding regarding identification and dissection, as well as needing a prolonged

operative time. Some authors believe the morbidity of an autologous muscle graft harvest is

lesser than that of the compromise of a motor branch in the residual limb. Furthermore, the risk

of a mismatch in nerve calibres is a potential source for axonal escape, which may result in a

symptomatic neuroma or into a loss of reinnervation (64–68). In both procedures, the nerve can

reinnervate and remodel itself within a denervated muscle segment, which provides many

targets for reinnervation and reduces the likelihood of disorganized axonal sprouting,

subsequently decreasing the risk of symptomatic neuroma formation (15,41,46,52).

It is important to mention that there have not been studies or systematic reviews which compare

TMR vs RPNI, so these are only technical aspects, not evidence of superiority.

Objectives

Primary objectives:

-    To determine the efficacy and safety of TMR and RPNI in treating patients with limb

amputation.

-    To compare which technique (TMR and RPNI) shows better results of efficacy and

safety in treating patients with limb amputations.

Secondary objectives:

-    To determine the efficacy and safety of TMR and RPNI across multiple relevant patient

characteristics. These include demography of the patients, age, sex, comorbidities,

amputation cause(s), amputation level, previous surgeries and if there was or not

previous nerve division into fascicles.

METHODS

For this protocol, we have followed methodological guidance from the Cochrane Handbook for

Systematic Reviews of Interventions (69) and we used the PRISMA-P checklist when writing our

report (70,71). For the review, we will follow methodological guidance from the Cochrane

Handbook for Systematic Reviews of Interventions (69) and MECIR (Methodological

Expectations for Cochrane Intervention Reviews) (72), and report the review following PRISMA

(73,74).

Criteria for considering studies for this review

Studies

This review will include all studies written in Spanish or English, randomized and non-

randomized, which involves clinical trials, cohort studies, case control studies, quasi-

experimental studies and case series (with n>10).

We will exclude case reports (detailed reports of an individual or handful of individuals), case

series (with n<10), qualitative studies (studies that collect and analyse non-numerical data) and

narrative reviews.

Participants

We will consider for inclusion participants that are adults (aged over 18 years) of any gender,

and with a superior or inferior major limb amputation of any aetiology.

Interventions

We will include the following five comparisons.

-    Targeted Muscle Reinnervation (TMR) versus classical amputation without further nerve

considerations.

-    Regenerative Peripheral Nerve Interface (RPNI) against classical amputation without

further nerve considerations.

-    Targeted Muscle Reinnervation versus regenerative Peripheral Nerve Interface.

-    Prophylactic versus curative TMR/RPNI

-    Case series (n>10) of prophylactic TMR/RPNI

Outcome measures

As no core outcome set has been established for effectiveness trials in amputation

reinnervation, a list of outcomes was generated based on existing systematic reviews

and primary observational studies identified through a preliminary search of the

literature (De Lange et al. (38), Mauch et al. (39), Zimbulis et al. (75), and Yuan et al.

(76)). The primary outcomes are neuroma incidence (present or not present), pain,

phantom limb pain (PLP) and residual limb pain (RLP) (with PROMIS and VAS scales,

and if it is or not present). All surgical complications will be analysed as secondary

outcomes (dehiscence, infection, haematoma, seroma, abscess, cardiac events, wound

healing complications, acute kidney disease, superficial wounds, operative stump

revisions and last mortality rate).

Search methods for identification of studies

We will search the following electronic databases:

- Web of Science (inception to present).

- Scopus (inception to present).

- PubMed (inception to present).

- Cochrane Register of Controlled Trials (CENTRAL) (inception to present).

To identify additional published, unpublished, and ongoing studies, we will:

- Check the reference lists of all relevant studies.

- Search in MedRxiv (inception to present)

- Contact authors, if appropriate.

Online supplemental material 1 demonstrates the complete search strategy.

DATA COLLECTION AND ANALYSIS

Selection of studies

We will assess all titles and abstracts identified during the literature searches, using Covidence

(77). Two review authors (JM, MR) will independently review the search results and identify

reports by screening all remaining titles and abstracts, excluding those that do not meet

inclusion criteria. Afterwards, we will retrieve the full text of the articles, and both review authors

will independently screen them for relevance and extract data. We will reach out to the

investigators to retrieve missing information when necessary. Any disagreements will be

resolved by discussion with the third author (DG).

The reasons for exclusion will be documented and presented at the full-text stage under the title

of 'Characteristics of excluded studies'.

Data extraction and management

The following data will be extracted from each study

- Administrative details: Study author(s), date of publication, year in which study was

conducted and presence of conflict of interest.

- Study characteristics: Study registration, study design type and sample size.

- Participants: Age, demography, sex, number of patients randomized, number lost to

follow-up/withdrawn, number analysed, previous surgeries and comorbidities.

-   Interventions: Type of amputation, cause of amputation, level of amputation and if there

was or not previous nerve division into fascicles.

-   Outcomes: Incidence of neuroma, incidence of PLP, incidence of RLP, severity of pain

and incidence of surgical complications.

Analysis will be performed with STATA 16 metan command (78).

Risk of bias assessment in included studies

Screening, data extraction and assessment of the risk of bias of included studies will be done

using validated tools and discussed below. Disagreements will be settled by consensus with the

fourth author (BH). Risk of bias will be estimated using recommendations in the Cochrane

Handbook for Systematic Reviews of Interventions, Version 6.5. Assessment of the risk of bias

in randomized trials will be estimated with the Risk of Bias 2 (RoB 2) tool (79). Assessment of

the risk of bias in a non-randomized study will be estimated with the Risk Of Bias In Non-

randomized Studies of Interventions version 2 (ROBINS-I V2) tool (80). Assessment of the risk

of bias in case series studies will be estimated with The Joanna Briggs Institute Checklist for

Case Series (81).

Measures of treatment effect

Measures of treatment effect have been chosen following the recommendations of Cochrane

Handbook for Systematic Reviews of Interventions, Version 6.5 (69). Dichotomous outcomes

will be synthesized and reported as an odds ratio (OR) with 95% confidence intervals (CI).

Continuous outcome data will be measured using mean difference with 95% confidence

intervals.

Dealing with missing data

The researchers of the original studies will be contacted to request any missing data, such as

sample sizes for analysis and actual numbers for outcomes presented in the figures. If this

proves to be unfeasible, the data will be excluded.

Assessment of heterogeneity and data analysis

The data will be firstly assessed for heterogeneity by visual appraisal of the presented forest

plots, and the I² index will be used to quantitatively evaluate heterogeneity among included

studies in each forest plot (82). Afterward, a meta-analysis will be performed with DerSimonian–

Laird method and random effects model (83).

If sufficient studies are available, we will undertake the following subgroup analyses as follows:

-   Sex.

-   Demography (ethnicity).

-   Cause of amputation is of great relevance as it is associated with the patient's risk of

276   mortality, the severity of the situation, other complications, etc.

277   -   Type of amputation.

278   -   Amputation level.

279   -   Presence of comorbidities (diabetes, coronary heart disease, peripheral arterial

280   disease, chronic kidney disease or congestive heart failure).

281   -   Previous nerve division into fascicles (it reduces the formation of aberrant reinnervation

282   and promotes proper reinnervation).

283   A cumulative meta-analysis will also be performed based on the year in which each study was

284   conducted (84).

285   For studying the age of participants, a meta-regression will be performed.

Assessment of reporting/publication biases

287   We will conduct a systematic, comprehensive search of the literature for both published and

288   unpublished studies to minimize the risk of publication bias.

289   If 10 or more studies are available. We will explore reporting bias graphically using a funnel plot,

290   and statistically by using the Egger's test to assess the symmetry of the funnel plot. Trim and fill

291   analysis will be performed to further assess the possible publication bias.

Sensitivity analysis

We will conduct sensitivity analyses to explore the methodological quality of studies, check

whether studies with a high risk of bias (in at least two domains) overestimate the effect of

treatment and to assess the robustness of our findings.

We will also perform a sensitivity analysis using the data from case series studies and the

prophylactic arms of studies comparing prophylactic vs. curative TMR/RPNI, to enhance the

sample size.

Summary of findings and assessment of the certainty of the evidence

300 We will use the GRADE approach, as outlined in the GRADE Handbook, to assess the certainty

301 of evidence regarding the clinical irrelevant outcomes outlined earlier in this document (85).

Ethics and dissemination

303 No ethical approval is needed for this review, as we will use data from previously published

304 studies. We will spread our research in national and international medical congresses and any

305 other non-conflicting means of publication.

Acknowledgments

The authors would like to thank Dr. Miguel Ruiz Canela (Professor of Preventive Medicine and

Public Health, University of Navarra) for his assistance advising us in the methods section.

1. Owings MF, Kozak LJ. Ambulatory and inpatient procedures in the United States, 1996.
Vital Health Stat 13. 1998 Nov;(139):1–119.

2. Ziegler-Graham K, MacKenzie EJ, Ephraim PL, Travison TG, Brookmeyer R. Estimating the
Prevalence of Limb Loss in the United States: 2005 to 2050. Archives of Physical Medicine
and Rehabilitation. 2008 Mar;89(3):422–9.

3. Ebrahimzadeh MH, Hariri S. Long-Term Outcomes of Unilateral Transtibial Amputations.
Military Medicine. 2009 Jun;174(6):593–7.

4. Bhuvaneswar CG, Epstein LA, Stern TA. Reactions to Amputation: Recognition and
Treatment: (Rounds in the General Hospital). Prim Care Companion J Clin Psychiatry. 2007
Aug 15;09(04):303–8.

5. Lastória S, Rollo HA, Yoshida WB, Giannini M, Moura R, Maffei FHA. Prophylaxis of deep-
vein thrombosis after lower extremity amputation: Comparison of low molecular weight
heparin with unfractionated heparin. Acta Cir Bras. 2006 Jun;21(3):184–6.

6. Huang ME, Johns JS, White J, Sanford K. Venous thromboembolism in a rehabilitation
setting after major lower-extremity amputation. Archives of Physical Medicine and
Rehabilitation. 2005 Jan;86(1):73–8.

7. Burke B, Kumar R, Vickers V, Grant E, Scremin E. Deep Vein Thrombosis After Lower Limb
Amputation: American Journal of Physical Medicine & Rehabilitation. 2000 Mar;79(2):145–
9.

8. Yeager RA, Moneta GL, Edwards JM, Taylor LM, McConnell DB, Porter JM. Deep vein
thrombosis associated with lower extremity amputation. Journal of Vascular Surgery. 1995
Nov;22(5):612–5.

9. Fang ZB, Hu FY, Arya S, Gillespie TW, Rajani RR. Preoperative frailty is predictive of
complications after major lower extremity amputation. Journal of Vascular Surgery. 2017
Mar;65(3):804–11.

10. Thorud JC, Plemmons B, Buckley CJ, Shibuya N, Jupiter DC. Mortality After Nontraumatic
Major Amputation Among Patients With Diabetes and Peripheral Vascular Disease: A
Systematic Review. The Journal of Foot and Ankle Surgery. 2016 May;55(3):591–9.

11. Fisher ES, Goodman DC, Chandra A. Disparities in Health and Health Care Among
Medicare Beneficiaries: A Brief Report of the Dartmouth Atlas Project. Lebanon (NH): The
Dartmouth Institute for Health Policy and Clinical Practice; 2008 Jun 20. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK586760/. In.

12. Bancks MP, Kershaw K, Carson AP, Gordon-Larsen P, Schreiner PJ, Carnethon MR.
Association of Modifiable Risk Factors in Young Adulthood With Racial Disparity in Incident
Type 2 Diabetes During Middle Adulthood. JAMA. 2017 Dec 26;318(24):2457.

13. Wu CL, Tella P, Staats PS, Vaslav R, Kazim DA, Wesselmann U, et al. Analgesic Effects of
Intravenous Lidocaine and Morphine on Postamputation Pain. Anesthesiology. 2002 Apr
1;96(4):841–8.

14. Heikkinen M, Saarinen J, Suominen VP, Virkkunen J, Salenius J. Lower limb amputations:
Differences between the genders and long-term survival. Prosthetics & Orthotics
International. 2007 Sep;31(3):277–86.

15. Nelson AW. The painful neuroma: The regenerating axon versus the epineural sheath.
Journal of Surgical Research. 1977 Sep;23(3):215–21.

16. Arnold DMJ, Wilkens SC, Coert JH, Chen NC, Ducic I, Eberlin KR. Diagnostic Criteria for
Symptomatic Neuroma. Ann Plast Surg. 2019 Apr;82(4):420–7.

17. Serrano Falcón C, Serrano Falcón M del M, Ruiz Villaverde R, Linares Solano J, Serrano
Ortega S. Amputation neuromas after neck surgery. Dermatol Online J. 2005 Aug
1;11(2):24.

18. Vlot MA, Wilkens SC, Chen NC, Eberlin KR. Symptomatic Neuroma Following Initial
Amputation for Traumatic Digital Amputation. The Journal of Hand Surgery. 2018
Jan;43(1):86.e1-86.e8.

19. Huang YJ, Assi PE, Drolet BC, Al Kassis S, Bastas G, Chaker S, et al. A Systematic
Review and Meta-analysis on the Incidence of Patients With Lower-Limb Amputations Who
Developed Symptomatic Neuromata in the Residual Limb. Ann Plast Surg. 2022
May;88(5):574–80.

20. Penna A, Konstantatos AH, Cranwell W, Paul E, Bruscino-Raiola F. Incidence and
associations of painful neuroma in a contemporary cohort of lower-limb amputees. ANZ
Journal of Surgery. 2018 May;88(5):491–6.

21. Fisher GT, Boswick JA. Neuroma Formation following Digital Amputations: The Journal of
Trauma: Injury, Infection, and Critical Care. 1983 Feb;23(2):136–42.

22. Van Der Avoort DJJC, Hovius SER, Selles RW, Van Neck JW, Coert JH. The incidence of
symptomatic neuroma in amputation and neurorrhaphy patients. Journal of Plastic,
Reconstructive & Aesthetic Surgery. 2013 Oct;66(10):1330–4.

23. Geraghty TJ, Jones LE. Painful neuromata following upper limb amputation. Prosthetics &
Orthotics International. 1996 Dec;20(3):176–81.

24. Kooijman CM, Dijkstra PU, Geertzen JHB, Elzinga A, Van Der Schans CP. Phantom pain
and phantom sensations in upper limb amputees: an epidemiological study. Pain. 2000
Jul;87(1):33–41.

25. Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel
expressed by sensory neurons. Nature. 1996 Jan;379(6562):257–62.

26. Nikolajsen L, Jensen TS. Phantom limb pain. British Journal of Anaesthesia. 2001
Jul;87(1):107–16.

27. Coward K, Plumpton C, Facer P, Birch R, Carlstedt T, Tate S, et al. Immunolocalization of
SNS/PN3 and NaN/SNS2 sodium channels in human pain states. Pain. 2000 Mar
1;85(1):41–50.

28. Ramachandran V. The perception of phantom limbs. The D. O. Hebb lecture. Brain. 1998
Sep 1;121(9):1603–30.

29. Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is
dependent on N -methyl-d-aspartic acid receptor activation; implications for the treatment of
post-injury pain hypersensitivity states. Pain. 1991 Mar;44(3):293–9.

30. Stover G, Prahlow N. Residual limb pain: An evidence-based review. Zasler N, editor. NRE.
2020 Nov 13;47(3):315–25.

31. Flor H. Phantom-limb pain: characteristics, causes, and treatment. The Lancet Neurology.
2002 Jul;1(3):182–9.

32. Nathanson M. Phantom limbs as reported by S. Weir Mitchell. Neurology. 1988
Mar;38(3):504–504.

33. Jackson MA, Simpson KH. Pain after amputation. Continuing Education in Anaesthesia
Critical Care & Pain. 2004 Feb;4(1):20–3.

34. Ehde DM, Czerniecki JM, Smith DG, Campbell KM, Edwards WT, Jensen MP, et al.
Chronic phantom sensations, phantom pain, residual limb pain, and other regional pain
after lower limb amputation. Archives of Physical Medicine and Rehabilitation. 2000
Aug;81(8):1039–44.

35. Hanley MA, Jensen MP, Smith DG, Ehde DM, Edwards WT, Robinson LR. Preamputation
Pain and Acute Pain Predict Chronic Pain After Lower Extremity Amputation. The Journal of
Pain. 2007 Feb;8(2):102–9.

36. Desmond DM, MacLachlan M. Affective Distress and Amputation-Related Pain Among
Older Men with Long-Term, Traumatic Limb Amputations. Journal of Pain and Symptom
Management. 2006 Apr;31(4):362–8.

37. Buchheit T, Van De Ven T, John Hsia HL, McDuffie M, MacLeod DB, White W, et al. Pain
Phenotypes and Associated Clinical Risk Factors Following Traumatic Amputation: Results
from Veterans Integrated Pain Evaluation Research (VIPER): Pain Phenotypes and
Associated Clinical Risk Factors. Pain Med. 2015 Jul;n/a-n/a.

38. De Lange JWD, Hundepool CA, Power DM, Rajaratnam V, Duraku LS, Zuidam JM.
Prevention is better than cure: Surgical methods for neuropathic pain prevention following
amputation – A systematic review. Journal of Plastic, Reconstructive & Aesthetic Surgery.
2022 Mar;75(3):948–59.

39. Mauch JT, Kao DS, Friedly JL, Liu Y. Targeted muscle reinnervation and regenerative
peripheral nerve interfaces for pain prophylaxis and treatment: A systematic review. PM&R.
2023 Nov;15(11):1457–65.

40. Kuiken TA, Dumanian GA, Lipschutz RD, Miller LA, Stubblefield KA. The use of targeted
muscle reinnervation for improved myoelectric prosthesis control in a bilateral shoulder
disarticulation amputee. Prosthetics & Orthotics International. 2004 Dec;28(3):245–53.

41. Cheesborough J, Smith L, Kuiken T, Dumanian G. Targeted Muscle Reinnervation and
Advanced Prosthetic Arms. Seminars in Plastic Surgery. 2015 Feb 4;29(01):062–72.

42. Kuiken TA, Barlow AK, Hargrove LJ, Dumanian GA. Targeted Muscle Reinnervation for the
Upper and Lower Extremity. Techniques in Orthopaedics. 2017 Jun;32(2):109–16.

43. Henderson JT, Koenig ZA, Climov M, Gelman J. Demystifying Targeted Muscle
Reinnervation: A Systematic Review of Nerve Transfers for the Lower Extremity. Plastic
and Reconstructive Surgery - Global Open. 2023 Mar;11(3):e4894.

44. Ryan DJ, Ayalon O, Hacquebord J. Targeted Muscle Reinnervation (TMR) and Other
Considerations in Upper Extremity Amputation. Bull Hosp Jt Dis (2013). 2022
Mar;80(1):25–30.

45. Janes LE, Fracol ME, Dumanian GA, Ko JH. Targeted Muscle Reinnervation for the
Treatment of Neuroma. Hand Clinics. 2021 Aug;37(3):345–59.

46. Hooper RC, Cederna PS, Brown DL, Haase SC, Waljee JF, Egeland BM, et al.
Regenerative Peripheral Nerve Interfaces for the Management of Symptomatic Hand and
Digital Neuromas. Plastic and Reconstructive Surgery - Global Open. 2020 Jun;8(6):e2792.

47. Kubiak CA, Kemp SWP, Cederna PS. Regenerative Peripheral Nerve Interface for
Management of Postamputation Neuroma. JAMA Surg. 2018 Jul 1;153(7):681.

48. FitzGerald JJ, Lago N, Benmerah S, Serra J, Watling CP, Cameron RE, et al. A
regenerative microchannel neural interface for recording from and stimulating peripheral
axons *in vivo*. J Neural Eng. 2012 Feb 1;9(1):016010.

49. Micera S, Carpaneto J, Raspopovic S. Control of Hand Prostheses Using Peripheral
Information. IEEE Rev Biomed Eng. 2010;3:48–68.

50. Svientek SR, Ursu DC, Cederna PS, Kemp SWP. Fabrication of the Composite
Regenerative Peripheral Nerve Interface (C-RPNI) in the Adult Rat. JoVE. 2020 Feb
25;(156):60841.

51. Kung TA, Bueno RA, Alkhalefah GK, Langhals NB, Urbanchek MG, Cederna PS.
Innovations in Prosthetic Interfaces for the Upper Extremity: Plastic and Reconstructive
Surgery. 2013 Dec;132(6):1515–23.

52. Kung TA, Langhals NB, Martin DC, Johnson PJ, Cederna PS, Urbanchek MG.
Regenerative Peripheral Nerve Interface Viability and Signal Transduction with an
Implanted Electrode. Plastic & Reconstructive Surgery. 2014 Jun;133(6):1380–94.

53. Vu PP, Vaskov AK, Irwin ZT, Henning PT, Lueders DR, Laidlaw AT, et al. A regenerative
peripheral nerve interface allows real-time control of an artificial hand in upper limb
amputees. Sci Transl Med. 2020 Mar 4;12(533):eaay2857.

54. Sando I, Leach M, Woo S, Moon J, Cederna P, Langhals N, et al. Regenerative Peripheral
Nerve Interface for Prostheses Control: Electrode Comparison. J reconstr Microsurg. 2015
Oct 26;32(03):194–9.

55. Irwin ZT, Schroeder KE, Vu PP, Tat DM, Bullard AJ, Woo SL, et al. Chronic recording of
hand prosthesis control signals via a regenerative peripheral nerve interface in a rhesus
macaque. J Neural Eng. 2016 Aug 1;13(4):046007.

56. Vu PP, Irwin ZT, Bullard AJ, Ambani SW, Sando IC, Urbanchek MG, et al. Closed-Loop
Continuous Hand Control via Chronic Recording of Regenerative Peripheral Nerve
Interfaces. IEEE Trans Neural Syst Rehabil Eng. 2018 Feb;26(2):515–26.

57. Vaskov AK, Vu PP, North N, Davis AJ, Kung TA, Gates DH, et al. Surgically Implanted
Electrodes Enable Real-Time Finger and Grasp Pattern Recognition for Prosthetic Hands.
IEEE Trans Robot. 2022 Oct;38(5):2841–57.

58. Urbanchek MG, Kung TA, Frost CM, Martin DC, Larkin LM, Wollstein A, et al. Development
of a Regenerative Peripheral Nerve Interface for Control of a Neuroprosthetic Limb. BioMed
Research International. 2016;2016:1–8.

59. Dhillon GS, Horch KW. Direct neural sensory feedback and control of a prosthetic arm.
IEEE Trans Neural Syst Rehabil Eng. 2005 Dec;13(4):468–72.

60. Kubiak CA, Adidharma W, Kung TA, Kemp SWP, Cederna PS, Vemuri C. "Decreasing
Postamputation Pain with the Regenerative Peripheral Nerve Interface (RPNI)". Annals of
Vascular Surgery. 2022 Feb;79:421–6.

61. Ives GC, Kung TA, Nghiem BT, Ursu DC, Brown DL, Cederna PS, et al. Current State of
the Surgical Treatment of Terminal Neuromas. NEUROSURGERY. 2018 Sep;83(3):354–
64.

62. Ursu D, Nedic A, Urbanchek M, Cederna P, Gillespie RB. Adjacent regenerative peripheral
nerve interfaces produce phase-antagonist signals during voluntary walking in rats. J
NeuroEngineering Rehabil. 2017 Dec;14(1):33.

63. Anand S, Desai V, Alsmadi N, Kanneganti A, Nguyen DHT, Tran M, et al. Asymmetric
Sensory-Motor Regeneration of Transected Peripheral Nerves Using Molecular Guidance
Cues. Sci Rep. 2017 Oct 30;7(1):14323.

64.   Leach GA, Dean RA, Kumar NG, Tsai C, Chiarappa FE, Cederna PS, et al. Regenerative
Peripheral Nerve Interface Surgery: Anatomic and Technical Guide. Plastic and
Reconstructive Surgery - Global Open. 2023 Jul;11(7):e5127.

65.   Cohen S, Hsu. Postamputation pain: epidemiology, mechanisms, and treatment. JPR. 2013
Feb;121.

66.   Valerio I, Schulz SA, West J, Westenberg RF, Eberlin KR. Targeted Muscle Reinnervation
Combined with a Vascularized Pedicled Regenerative Peripheral Nerve Interface. Plastic
and Reconstructive Surgery - Global Open. 2020 Mar;8(3):e2689.

67.   Wimalawansa SM, Lygrisse D, Anderson SR, Eberlin KR, Westenberg R, Schulz S, et al.
Targeted Muscle Reinnervation in Partial Hand Amputations. Plastic and Reconstructive
Surgery - Global Open. 2021 May 28;9(5):e3542.

68.   Lee E, Wong AL, Pinni S, Von Guionneau N, Harris TGW, Kothari R, et al. Improving Nerve
Coaptation Outcomes in Targeted Muscle Reinnervation: A Novel Bioengineered Device.
Plastic and Reconstructive Surgery - Global Open. 2021 Oct 20;9(10S):99–100.

69.   Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors).
Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August
2024). Cochrane, 2024. Available from www.training.cochrane.org/handbook.

70.   Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred
reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015:
elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647–g7647.

71.   PRISMA-P Group, Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, et al. Preferred
reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015
statement. Syst Rev. 2015 Dec;4(1):1.

72.   Higgins JPT, Lasserson T, Chandler J, Tovey D, Thomas J, Flemyng E, Churchill R.
Methodological Expectations of Cochrane Intervention Reviews. Cochrane: London,
Version February 2021. https://community.cochrane.org/mecir-manual.

73.   Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020
explanation and elaboration: updated guidance and exemplars for reporting systematic
reviews. BMJ. 2021 Mar 29;n160.

74.   Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021
Mar 29;n71.

75.   Zimbulis AJ, An VVG, Symes M, Duraku LS, Gaston RG, Eberlin KR, et al. Targeted
Muscle Reinnervation Compared to Standard Peripheral Nerve Management Following
Amputation: A Systematic Review and Meta-Analysis. Hand (New York, N,Y). 2024 Oct
29;15589447241284811.

76.   Mauch JT, Kao DS, Friedly JL, Liu Y. Targeted muscle reinnervation and regenerative
peripheral nerve interfaces for pain prophylaxis and treatment: A systematic review. PM&R.
2023 Nov;15(11):1457–65.

77.   Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia.
Available at www.covidence.org.

78.   StataCorp. 2019. Stata: Release 16. Statistical Software. College Station, TX: StataCorp
LLC.

79.   Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of
bias in a randomized trial [last updated October 2019]. In: Higgins JPT, Thomas J,

Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for
Systematic Reviews of Interventions version 6.5. Cochrane, 2024. In.

80. Ref ID: ROBINS-I V2 Ref type: Other Authors: ROBINS-I V2 Development Group English
title: ROBINS-I V2 Journal/book/source: https://www.riskofbias.info/welcome/robins-i-v2
Date of publication: (accessed 12 December 2024) [add appropriate date].

81. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R,
Mattis P, Lisy K, Mu P-F. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris
E, Munn Z (Editors). Joanna Briggs Institute Reviewer's Manual. The Joanna Briggs
Institute, 2017. Available from https://reviewersmanual.joannabriggs.org/.

82. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE
guidelines: 7. Rating the quality of evidence—inconsistency. Journal of Clinical
Epidemiology. 2011 Dec;64(12):1294–302.

83. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemporary Clinical
Trials. 2015 Nov;45:139–45.

84. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis
[Internet]. 1st ed. Wiley; 2009 [cited 2024 Nov 29]. Available from:
https://onlinelibrary.wiley.com/doi/book/10.1002/9780470743386

85. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading
quality of evidence and strength of recommendations for diagnostic tests and strategies.
BMJ. 2008 May 17;336(7653):1106–10.

FOOTNOTES
Author statement

DG is the guarantor of the review, JM and DG initiated the review, drafted and finalised the
background, objectives and methods sections. All authors read and approved the final version
of the manuscript.

Funding

This research received no specific grant from any funding agency in the public, commercial or
not-for-profit sectors.

Conflicts of interests

None declared.

Patient consent for publication

Not required.